Novo Nordisk remains coy over Wegovy blockbuster potential
![Lars Fruergaard Jørgensen, CEO of Novo Nordisk | Photo: Stine Bidstrup/ERH](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13975957.ece/ALTERNATES/schema-16_9/doc7kte2o5fvwz1iegrv8w7.jpg)
With last Friday’s release of Novo Nordisk’s quarterly report for 2021, the pharmaceutical firm chose to reveal the actual sales figures for obesity drug Wegovy for the first time.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk unveils Wegovy sales
For subscribers
Novo Nordisk subsupplier reinitiates Wegovy production
For subscribers